Protein Phosphorylation by Serine/Threonine Kinases in Insulin Signaling Pathways
AssigneeCell Signaling Technology, Inc.
InventorsAilan Guo, Albrecht Moritz, Anthony Possemato, Charles Farnsworth, Hong Ren, Jing Zhou, John Rush, Klarisa Rikova, Matthew Stokes, Valerie Goss, Yu Li
Life of this patent
Estimating the term…
Abstract
The invention discloses 137 novel phosphorylation sites identified in insulin signaling pathways, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.
Claims3
An antibody or antigen-binding fragment thereof, wherein the antibody specifically binds to an amino acid sequence comprising a phosphorylation site identified in Table 1 when the serine or threonine in Column D is phosphorylated, and wherein the antibody does not bind to said amino acid sequence when the serine or threonine is not phosphorylated;
- wherein the amino acid sequence comprises a serine or threonine phosphorylation site selected from the group consisting of SEQ ID NOs:
- 12 (Tks5);
- 44 (DAB2IP);
- 51 (TBC1D22B);
- 76 (TPCN1);
- 82 (PDCD11);
- 83 (vigilin);
- 84 (PDAP1);
- 86 (DDX17);
- 103 (FAM44A);
- 125 (DKFZp564C1);
- and 118 (C18orf25).
An antibody or antigen-binding fragment thereof, wherein the antibody specifically binds to an amino acid sequence comprising a phosphorylation site identified in Table 1 when the serine or threonine in Column D is not phosphorylated, and wherein the antibody does not bind to said amino acid sequence when the serine or threonine is phosphorylated;
- wherein the amino acid sequence comprises a serine or threonine phosphorylation site selected from the group consisting of SEQ ID NOs:
- 12 (Tks5);
- 44 (DAB2IP);
- 51 (TBC1D22B);
- 76 (TPCN1);
- 82 (PDCD11);
- 83 (vigilin);
- 84 (PDAP1);
- 86 (DDX17);
- 103 (FAM44A);
- 125 (DKFZp564C1);
- and 118 (C18orf25).
Dependencies are inferred from the claim text.